The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

BACKGROUND: The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC). Multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Fidler, Mary Jo, Fhied, Cristina L., Roder, Joanna, Basu, Sanjib, Sayidine, Selina, Fughhi, Ibtihaj, Pool, Mark, Batus, Marta, Bonomi, Philip, Borgia, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861613/
https://www.ncbi.nlm.nih.gov/pubmed/29558888
http://dx.doi.org/10.1186/s12885-018-4193-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861613/
https://www.ncbi.nlm.nih.gov/pubmed/29558888
http://dx.doi.org/10.1186/s12885-018-4193-0

Ejemplares similares